Efficacy of Exercise Thallium-201 Scintigraphy in the Diagnosis and Prognosis of Coronary Artery Disease

doi:10.1059/0003-4819-113-9-703

Efficacy of Exercise Thallium-201 Scintigraphy in the Diagnosis and Prognosis of Coronary Artery Disease

Excerpt

This Clinical Efficacy Assessment Project report analyzes the safety and efficacy of exercise thallium-201 myocardial perfusion scintigraphy (thallium scintigraphy) in the diagnosis and prognosis of patients with suspected coronary artery disease and documented myocardial infarction.

Rationale and Description Thallium scintigraphy is most often done as an adjunct to conventional exercise electrocardiography (ECG) to aid in the diagnosis, prognosis, and functional evaluation of patients with known or suspected coronary artery disease. The patient is given an intravenous dose of thallium-201, ranging from 2.0 to 3.5 mCi, at the peak of exercise. Exercise is continued for an additional 30 to 60 seconds

This 100-word excerpt has been provided in the absence of an abstract.

Acknowledgments

Acknowledgments: The Clinical Efficacy Assessment Project (CEAP) of the American College of Physicians evaluates and informs College members and others about the safety and efficacy of diagnostic and therapeutic modalities and medical practices. Evaluation of technologies begins with a notice in Annals of Internal Medicine and ACP Observer inviting comments. Appropriate members of the Council of Medical Societies, the Council of Subspecialty Societies, other specialty societies, and selected outside experts are asked to review draft manuscripts. The CEAP statements thus represent a synthesis of the literature and expert opinion and are intended to reflect the current state-of-the-art knowledge concerning a technology or medical practice. Statements may be reconsidered as new information becomes available.

Article and Author Information

↵* This paper was authored by Todd S. Kotler, MD, George A. Diamond, MD, Earl P. Steinberg, MD, and Lockhart B. McGuire, MD, and was developed for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: Lockhart B. McGuire, MD, Chair; Paul Calabresi, MD; Ernest L. Mazzaferri, MD; Albert G. Mulley, Jr., MD; Charles C. Smith, Jr., MD; Harold C. Sox, Jr., MD; Earl P. Steinberg, MD. Members of the Health and Public Policy Committee were: Paul F. Griner, MD, Chair; Thomas P. Almy, MD; F. Daniel Duffy, MD; John M. Eisenberg, MD; Richard G. Farmer, MD; Donald I. Feinstein, MD; C.S. Lewis, MD; Lockhart B. McGuire, MD; Steven A. Schroeder, MD; Lynn B. Tepley, MD; Quentin D. Young, MD. This paper was approved by the Board of Regents on 15 July 1989.
All previous CEAP statements and a subscription to future reports are now available in Clinical Efficacy Reports. This paper represents the second to be distributed in the 1990/91 subscription series.
Requests for Reprints: Linda Johnson White, Director, Department of Scientific Policy, American College of Physicians, Independence Mall West, Sixth Street at Race, Philadelphia, PA 19106-1572.